Literature DB >> 3485164

Calcium-specific immunoassays for factor IX: reduced levels of antigen in patients with vitamin K disorders.

G L Bray, A F Weinmann, A R Thompson.   

Abstract

Polyclonal rabbit anti-factor IX antisera were fractionated to establish solid-phase immunoassays recognizing calcium-dependent and non-calcium-dependent epitopes. The assays were greater than 99.9% specific for factor IX and sensitive to 0.05 U/dl plasma or 2 ng/ml purified factor IX. For the calcium-dependent fraction, an absolute requirement of divalent metal ions was found, and Sr(II), Mn(II), and Mg(II) could substitute for Ca(II). On immunoblots of reduced, electrophoresed factor IXa, the 125I-calcium-dependent antibody fraction bound to the amino-terminal light chain. Plasma sampled from 13 patients receiving warfarin and one with cephalosporin-related vitamin K deficiency had a mean level of calcium-dependent factor IX antigen of 22 U/dl, comparable to the 24 jU/dl average of factor IX procoagulant activity; these two results were highly correlated. Antigen levels determined by either the polyclonal or a monoclonal, non-calcium-dependent anti-factor IX assays ranged from 1.7-fold to 6.0-fold greater than the corresponding levels of factor IX procoagulant activity or calcium-dependent antigen level for each subject's plasma. The difference reflects inactive, circulating factor IX. In contrast, factor IX antigen levels determined by an assay using a monoclonal, calcium-dependent anti-factor IX were from one half to one thirteenth as much as those measured by the polyclonal, calcium-dependent immunoassay. The disparity between results of calcium-dependent assays suggests that some Gla residues near the amino terminus of factor IX are relatively less important for normal procoagulant function of factor IX than others, are more sensitive to the effects of vitamin K antagonism or deficiency, and are important for the epitope recognized by this particular calcium-dependent, monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485164

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.

Authors:  B G Schach; S Yoshitake; E W Davie
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  CG dinucleotide transitions in the factor IX gene account for about half of the point mutations in hemophilia B patients: a Seattle series.

Authors:  S H Chen; M Zhang; E W Lovrien; C R Scott; A R Thompson
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

3.  Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.

Authors:  S H Chen; A R Thompson; M Zhang; C R Scott
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B.

Authors:  D Armentano; A R Thompson; G Darlington; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.

Authors:  G L Bray; A R Thompson
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.